Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks : A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Puig Sanz, Lluís ![Identificador ORCID](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Costanzo, Antonio ![Identificador ORCID](/img/uab/orcid.ico)
(Humanitas Clinical and Research Center IRCCS)
de Jong, Elke M. G. J. (Radboud University Medical Center)
Torres, Tiago ![Identificador ORCID](/img/uab/orcid.ico)
(University of Porto)
Warren, Richard B. ![Identificador ORCID](/img/uab/orcid.ico)
(The University of Manchester)
Wapenaar, Robert (Janssen-Cilag BV (Breda, Països Baixos))
Wegner, Sven (Janssen-Cilag GmbH (Neuss, Alemanya))
Gorecki, Patricia (Janssen-Cilag Ltd (High Wycombe, Regne Unit))
Gramiccia, Talia (Janssen-Cilag SpA (Milà, Itàlia))
Jazra, Maria (Janssen-Cilag (París, França))
Buyze, Jozefien (Janssen Pharmaceutica NV (Beerse, Bèlgica))
Conrad, Curdin (University of Lausanne)
Universitat Autònoma de Barcelona
Data: |
2023 |
Resum: |
Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices. This post-hoc analysis of the 5-year VOYAGE 1 clinical trial compares baseline characteristics of patients maintaining a Psoriasis Area and Severity Index (PASI) score of 0 at all visits for ≥ 156 consecutive weeks (PASI = 0 group) with those that never achieve PASI = 0 (comparator group), using descriptive statistics and a multiple logistic regression model. Guselkumab plasma trough concentrations in both response groups were assessed from Weeks 4-156. Of patients who started guselkumab treatment at Week 0 or at Week 16 after switching from placebo, 22. 7% (112/494) maintained PASI = 0 for ≥ 156 consecutive weeks. Numerical differences in baseline characteristics, including age, obesity, diabetes, PASI score, disease duration, smoking status, and psoriatic arthritis comorbidity, were identified between the PASI = 0 group and comparator group. Plasma guselkumab levels were consistently higher in the PASI = 0 group. Multiple logistic regression analysis revealed absence of diabetes, lower Dermatology Life Quality Index score at baseline, and higher Week 4 guselkumab plasma concentration as significantly (p < 0. 05) associated with the PASI = 0 group. A substantial (22. 7%) number of guselkumab-treated patients in the VOYAGE 1 clinical trial maintained complete skin clearance for a consecutive period of ≥ 156 weeks. Factors associated with this outcome may suggest clinical benefits of holistic treatment approaches. NCT02207231. |
Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by-nc.ico) |
Llengua: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Publicat a: |
American Journal of Clinical Dermatology, Vol. 25 (october 2023) , p. 315-325, ISSN 1179-1888 |
DOI: 10.1007/s40257-023-00816-1
PMID: 37804472
El registre apareix a les col·leccions:
Documents de recerca >
Documents dels grups de recerca de la UAB >
Centres i grups de recerca (producció científica) >
Ciències de la salut i biociències >
Institut de Recerca Sant PauArticles >
Articles de recercaArticles >
Articles publicats
Registre creat el 2024-04-24, darrera modificació el 2024-06-18